- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in immunotherapy for hepatocellular carcinoma
Authors
Keywords
Hepatocellular carcinoma, Immunotherapy, Immune checkpoint inhibitor, Adoptive cellular therapy, Immune evasion, Combination therapy, Predictive biomarkers
Journal
Hepatobiliary & Pancreatic Diseases International
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-07-24
DOI
10.1016/j.hbpd.2021.06.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib
- (2021) May Tun Saung et al. ONCOLOGIST
- Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
- (2020) Pei-Chang Lee et al. Cancers
- Peptide vaccine as an adjuvant therapy for glypican‐3 positive hepatocellular carcinoma induces peptide specific CTLs and improves long prognosis
- (2020) Masatake Taniguchi et al. CANCER SCIENCE
- Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials
- (2020) Donghua Shi et al. CLINICAL CANCER RESEARCH
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Driving CAR T cell translation forward
- (2019) Liora Schultz et al. Science Translational Medicine
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- The global pipeline of cell therapies for cancer
- (2019) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
- (2019) Heng-Huan Lee et al. CANCER CELL
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
- (2019) Zuzana Macek Jilkova et al. Clinical and Translational Gastroenterology
- The Natural Cytotoxicity Receptors in Health and Disease
- (2019) Alexander David Barrow et al. Frontiers in Immunology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-7 enhances anti-tumor activity of CD8 + T cells in patients with hepatocellular carcinoma
- (2018) Dengke Teng et al. CYTOKINE
- Chimeric antigen receptor-engineered T-cell therapy for liver cancer
- (2018) Yang Chen et al. Hepatobiliary & Pancreatic Diseases International
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
- (2018) Anton Uryvaev et al. MEDICAL ONCOLOGY
- Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
- (2018) Min Yu et al. MOLECULAR THERAPY
- Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
- (2018) Ritu Shrestha et al. Frontiers in Oncology
- Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome
- (2018) Mohammed Alnaggar et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
- (2018) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.
- (2018) Luigi Buonaguro et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for the treatment of hepatocellular carcinoma
- (2018) Fabian Finkelmeier et al. Expert Review of Anticancer Therapy
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application
- (2018) Nancy Tray et al. Cancer Immunology Research
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies
- (2017) Anthony F. Daniyan et al. Nature Reviews Clinical Oncology
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer
- (2017) Mao Lin et al. Oncotarget
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
- (2016) Pei-Yu Huang et al. Oncotarget
- Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
- (2016) Dong-Qiang Zeng et al. Oncotarget
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
- (2015) S. C. Katz et al. CLINICAL CANCER RESEARCH
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
- (2015) Douglas B Johnson et al. Immunotherapy
- Immune Checkpoint Blockade in Hepatocellular Carcinoma
- (2015) Liver Cancer
- A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
- (2015) J Randolph Hecht et al. Journal for ImmunoTherapy of Cancer
- Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
- (2014) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic Strategies
- (2014) Salem Chouaib et al. Frontiers in Immunology
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC
- (2012) Mervat El Ansary et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Therapeutic Cancer Vaccines
- (2011) Marijo Bilusic et al. AMERICAN JOURNAL OF THERAPEUTICS
- Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity
- (2011) A. Pievani et al. BLOOD
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells
- (2011) Katarzyna Karwacz et al. EMBO Molecular Medicine
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
- (2010) Jan Spanholtz et al. PLoS One
- The Role of Regulatory T Cells in Cancer
- (2010) Tai-You Ha Immune Network
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma
- (2008) Dong Hui et al. DIGESTIVE AND LIVER DISEASE
- Chinese health biotech and the billion-patient market
- (2008) Sarah E Frew et al. NATURE BIOTECHNOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started